• Users Online: 48
  • Print this page
  • Email this page
Year : 2016  |  Volume : 9  |  Issue : 1  |  Page : 39-56

Novel systemic therapy in advanced non-small-cell lung cancer

1 Department of Medical Oncology, Gral Medical, Bucharest, Romania, Medical University Vienna International, Vienna, Austria
2 Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna and General Hospital, Vienna, Austria

Correspondence Address:
Christoph C Zielinski
Department of Medicine I, Medical University Vienna, Währinger Gürtel 18–20, 1090, Vienna
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7707/hmj.615

Rights and Permissions

Standard chemotherapy regimes (platinum-based combinations) for advanced non-small-cell lung cancer have reached their therapeutic limits. In the last few years standard chemotherapy has been supplemented by targeted therapy. Targeted therapy consists of tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) mutation-positive tumours or ALK (anaplastic lymphoma kinase)-rearranged tumours as well as antiangiogenic TKIs and monoclonal antibodies directed against vascular endothelial growth factor, vascular endothelial growth factor receptor 2 or EGFR. Although targeted therapy has made remarkable progress, there is great hope for the use of immune checkpoint inhibitors, which specifically enhance the immune response directed against the tumour.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal